Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 1, 2003, Pages 133-140

  Gardner, J D ^a   Sloan, S ^b   Robinson, M ^c   Miner Jr , P B ^c  

^a Science for Organizations Inc   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; STOMACH PH; TEST MEAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS;

EID: 0041346507     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01644.x     Document Type: Article

References (18)

1. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-45.
2. Robinson M. Medical management of gastroesophageal reflux disease. In: Castell DO, Richter JE, eds. The Esophagus, 3rd edn. Lippincott, Williams & Wilkins. Philadelphia, 1999: 447-62.
3. Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of GERD. Am J Gastroenterol 2001; 96: 1363-70.
4. Gardner JD, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: 455-64.
5. Gardner JD, Sloan S, Miner PB Jr, Robinson M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastroesophageal reflux disease. Aliment Pharmacol Ther 2003; 17: 945-53.
6. Gardner JD, Sloan S, Miner PB Jr, Robinson M. Determination of the reduction in gastric acidity necessary to prevent pathologic esophageal reflux in GERD patients treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 17: 955-64.
7. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-93.
8. McNeil BJ, Keeler E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med 1975; 293: 211-5.
9. Hanley JA, McNeil BJ. A method of comparing the areas under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
10. Hanley JA, McNeil BJ. The meaning and use of the area under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
11. Motulsky H. Interpreting laboratory tests: Introduction to Bayesian thinking. In: Intuitive Biostatistics. Oxford University Press, New York, 1995: 129-39.
12. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
13. Schindlbeck NE, Heinrich C, Konig A, Dendoffer A, Pace F, Muller-Lissner SA. Optimal thresholds, sensitivity, and specificity of long-term pH-metry for detection of gastroesophageal reflux disease. Gastroenterology 1987; 93: 85-90.
14. Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h esophageal monitoring, normal values, optimal-thresholds, specificity, sensitivity, and reproducibility. Am J Gstroenterol 1992; 87: 1102-11.
15. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201.
16. Hedenstrom H, Alm C, Kraft M, Grahnen A. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 1997; 11: 1137-41.
17. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386-406.
18. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987; 28: 1484-8.